That was kind of what I was trying to address there.
The life science strategy, from what I understand, is really looking at a number of things. It supports research that's happening at the universities and then takes it into clinical development. At the same time, it invests into commercial industry—commercial manufacturers like Sanofi and Biovectra—and the resilience and upsell investments that we have seen recently, to allow commercial manufacturing.
It's a strategy that enables innovation to occur and to go into development. It then ensures that there is enough commercial manufacturing capacity in the country available to then produce those therapeutics and vaccines. It's a very important strategy. If you'll allow me, I'll address a few other points that I think are critical.
As we move forward, it is critical for the country to think about the fact that investment into the infrastructure is effective only if there is also investment into the operating support. The MSI program is one of those arms that obviously works to support those facilities. Unfortunately, for many facilities, that is only 60% of the operating cost, and it doesn't cover the expenses for research or even the researchers who are doing the work.
Another element, as we've heard before, is training. We need to train the next generation of our researchers. We need to have national training programs to ensure that we have enough workers who can do the critical work. During the pandemic, it was very hard for us to even find individuals who were willing to work day and night and weekends in level 3 conditions, which are conditions under which you can't go to the bathroom, you can't eat, you can't drink and so on.
Then the last one is to really ensure that there is good interaction between the manufacturing industry and our universities and small biotech.
I'm sorry for stealing your time.